CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Axovant Gene Therapies Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Axovant Gene Therapies Ltd
Suite 1
3rd Floor, 11-12 St. James's Square
Phone: +44 2033189708p:+44 2033189708 LONDON, SW1Y 4LB  United Kingdom Ticker: AXGTAXGT

Business Summary
Axovant Gene Therapies Ltd., formerly Axovant Sciences Ltd., is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. Its AXO-Lenti-PD is an in vivo lentiviral gene therapy investigational product candidate and being developed for the one-time treatment of Parkinson’s disease.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20193/31/2019YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Frank M.Torti 40 9/26/2018 9/26/2018
Chief Executive Officer, Director PavanCheruvu 37 9/26/2018 2/12/2018
Principal Financial and Accounting Officer David W.Nassif 65 7/1/2019 7/1/2019
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Axovant Sciences Inc. 11 Times Square New York NY United States

Business Names
Business Name
AXGT
AXON
Axovant Holdings Ltd.
6 additional Business Names available in full report.

General Information
Number of Employees: 57 (As of 3/31/2019)
Outstanding Shares: 22,791,669 (As of 11/6/2019)
Shareholders: 2
Stock Exchange: NASD


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 06, 2019